Latest 8-K filings

NASDAQ
PowerCompute, Inc. has amended its Form 8-K to correct a reporting error and detail a new $18.13 million loan facility secured by Bitcoin, significantly reducing interest expenses.
NYSE
BorgWarner Inc. has commenced cash tender offers for its outstanding 7.125% Senior Notes due 2029 and up to $720 million of other senior notes as part of a balanced capital allocation strategy.
NYSE
Innovate Corp. announced an agreement to sell its DBM Global subsidiary for $650 million in cash and stock, a move intended to significantly reduce the company's outstanding debt.
NASDAQ
Sight Sciences, Inc. announced the appointment of Kashif Rashid as Chief Legal Officer and Corporate Secretary, effective August 10, 2026, alongside the departure of Jeremy Hayden.
NYSE
Onto Innovation Inc. has successfully acquired a 27% minority equity stake in Rigaku Holdings Corporation for approximately $720 million, deepening their strategic collaboration in X-ray process control for semiconductor manufacturing.
NASDAQ
SHF Holdings, Inc. announced second quarter 2026 results, highlighting a 4.8% year-over-year revenue increase to $1.9 million, driven by loan program income, while also reporting a net loss of $1.5 million.
NYSE
CoreCivic has entered into an accelerated share repurchase agreement to buy back $500 million of its common stock, alongside updated full-year 2026 financial guidance.
OID
Latch, Inc. announced its second quarter 2026 financial results, highlighting a 16.8% year-over-year increase in software revenue to $6.1 million, a 12.1% narrowing of its net loss to $(6.9) million, and improved quarterly cash usage.
NASDAQ
Jerash Holdings announced record revenue of $50.2 million and a more than fivefold increase in net income for its fiscal 2027 first quarter, driven by strong demand and improved operational efficiencies.
NASDAQ
Sphere 3D Corp. has implemented a limited-duration shareholder rights plan to ensure fair treatment of all shareholders in the event of a take-over bid.
NASDAQ
Powerfleet announced first quarter fiscal 2027 results, highlighting a 9.1% increase in services revenue to $94.3 million and a 79% rise in operating cash flow to $8.4 million, alongside significant acceleration in its South African National Treasury contract.
NASDAQ
Clene Inc. announced new biomarker analyses from its CNM-Au8 trials, showing a correlation between NfL biomarker response and improved survival and function in ALS patients, which will be included in its upcoming NDA submission for accelerated approval.
NASDAQ
Quanterix reported Q2 2026 revenue of $32.9 million, missing expectations, and revised its full-year revenue guidance downwards, while also extending its cash-flow break-even target to 2027.
NASDAQ
Cogent Biosciences announced strong Q2 2026 financial results, highlighting progress in bezuclastinib development for GIST and Systemic Mastocytosis, with key PDUFA dates approaching and a cash runway extending into late 2028.
NYSE
California Resources Corporation announced robust second quarter 2026 financial and operating results, highlighted by strategic acquisitions, operational efficiencies, and progress in carbon capture initiatives.
NYSE
Archer Aviation Inc. announced a definitive agreement to acquire Boeing's Wisk Aero, SkyGrid, and Insitu subsidiaries, creating a comprehensive AI platform for aerospace and defense, with Boeing taking a strategic stake.
NASDAQ
Beyond Meat has entered into a Second Supplemental Indenture to amend its 7.00% Convertible Senior Secured Second Lien PIK Toggle Notes due 2030, adjusting debt repurchase restrictions and extending a make-whole period.
NASDAQ
Outdoor Holding Company reported a significant turnaround in its fiscal first quarter of 2027, with revenue up 22.1% and a return to profitability, driven by strong marketplace performance and new revenue streams.
NASDAQ
Conduent Incorporated announced its second quarter 2026 financial results, reporting $531 million in revenue and a net loss, while also detailing progress on its transformation plan and portfolio optimization through divestitures.
NASDAQ
Park Dental Partners, Inc. has entered into a definitive agreement to acquire the dental services organization supporting Village Family Dental, marking its entry into North Carolina.
NYSE
Applied Aerospace & Defense announced the appointment of Chris Rogers to President and Chief Strategy Officer, effective July 27, 2026, to support accelerated growth.
NASDAQ
Evolv Technologies Holdings, Inc. announced the preliminary approval of a settlement for stockholder derivative claims, resolving multiple lawsuits without requiring payment from the company.
Yorkville Acquisition Corp. announced the mutual termination of its business combination agreement with Trump Media & Technology Group Corp. (TMTG) and Crypto.com due to market conditions.
NASDAQ
Telomir Pharmaceuticals announced the publication of peer-reviewed preclinical data demonstrating Telomir-Zn's efficacy in suppressing tumor growth and metastasis in prostate and triple-negative breast cancer models.
NASDAQ
Heron Therapeutics announced Q2 2026 results with mixed revenue performance, withdrew full-year financial guidance, and is exploring strategic alternatives.
NASDAQ
Strategy Inc reported on August 10, 2026, an update on its at-the-market offering, bitcoin sales, and share repurchase programs, highlighting substantial capital raised and a robust USD Reserve.
NYSE
MarineMax, Inc. has entered into a definitive agreement to be acquired by Safe Harbor Marinas, a Blackstone Infrastructure portfolio company, for $53.00 per share in an all-cash transaction valued at approximately $1.5 billion.
NASDAQ
Byrna Technologies Inc. has completed the acquisition of substantially all assets from Hero Defense Systems, LLC, bolstering its less-lethal defense product portfolio.
NASDAQ
Motorcar Parts of America reported a net loss for its fiscal 2027 first quarter, with net sales down year-over-year, but reaffirmed its full-year financial guidance.
NASDAQ
Silence Therapeutics plc reported positive topline results from the Phase 2 SANRECO trial of divesiran for polycythemia vera, meeting primary and secondary endpoints and supporting advancement to Phase 3.